References
- Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892. doi: 10.1182/blood.2020008824.
- Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–1143. doi: 10.1182/blood.2020006965.
- Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236–252. doi: 10.1182/blood.2021012251.
- Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28(9):1785–1790. doi: 10.1038/s41591-022-01911-2.
- Havers FP, Patel K, Whitaker M, et al. Laboratory-confirmed COVID-19-associated hospitalizations among adults during SARS-CoV-2 Omicron BA.2 variant predominance – COVID-19-Associated Hospitalization Surveillance Network, 14 states, June 20, 2021–May 31, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(34):1085–1091. doi: 10.15585/mmwr.mm7134a3.
- Nguyen THO, Rowntree LC, Allen LF, et al. Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. Cell Rep Med. 2023;4(4):101017. doi: 10.1016/j.xcrm.2023.101017.
- Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773–2787. doi: 10.1182/blood.2022017257.
- Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of covid-19. N Engl J Med. 2022;386(23):2188–2200. doi: 10.1056/NEJMoa2116620.
- Stuver R, Shah GL, Korde NS, et al. Activity of AZD7442 (tixagevimab–cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022;40(6):590–591. doi: 10.1016/j.ccell.2022.05.007.
- Kertes J, Shapiro Ben David S, Engel-Zohar N, et al. Association between AZD7442 (tixagevimab–cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality. Clin Infect Dis. 2022;76(3):e126–e132.
- James A. Davis, Katelynn Granger, Kiera Roubal, et al. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. Blood. 2023;141(2):200–203. doi: 10.1182/blood.2022018283.
- Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593–602. doi: 10.1038/s41586-022-04980-y.
- U.S. Food and Drug Administration; 2023. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us#:∼:text=Therefore%2C%20on%20June%2029%2C%202022,if%20patients%20need%20ongoing%20protection